
|Articles|May 15, 2005
Genetic, molecular anomalies determine RCC therapy
Management of kidney cancer is advancing on several fronts, and this theme of continued progress is well illustrated by research being presented at the AUA annual meeting, said Robert C. Flanigan, MD.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement




















